NovaBridge Biosciences (NBP) Status update summary

Business Model and Strategy

• Operates a global hub-and-spoke biotech platform, licensing innovative assets from China and building U.S.-based development teams.

• Focuses on clinical or clinical-ready stage programs to reduce biology risk and maximize asset value.

• Maintains a healthy cash position of $228 million, providing operational runway through 2028 and supporting key clinical milestones.

• Leadership team includes experienced executives and renowned ophthalmology specialists.

• NovaBridge is the majority shareholder of Visara, which controls global rights to VIS-101 outside Greater China and certain Asian countries.

VIS-101 Clinical Data and Results

• VIS-101 is a tetravalent bispecific antibody targeting VEGF-A and ANG-2, designed for best-in-class durability and efficacy in retinal vascular diseases.

• Phase 2a study in wet AMD (n=38) showed mean BCVA improvement over 10 ETDRS letters and median CST reduction of 100-150 μm after three loading doses.

• Up to 70% of treatment-naive patients were retreatment-free at four months, and about 40-50% at six months post-loading dose, indicating best-in-class durability.

• VIS-101 demonstrated a favorable safety profile with no dose-limiting toxicities; adverse events were mild and manageable, with 0% in the 3 mg group and 8% in the 6 mg group.

• Durability and efficacy compare favorably to leading therapies such as faricimab, with fewer loading doses and extended treatment-free intervals.

Clinical Development and Next Steps

• Phase 2b dose-ranging study for VIS-101 is expected to initiate in the second half of 2026, comparing 6 mg and 9 mg doses for safety, efficacy, and durability.

• A global Phase 3 program is planned to begin in 2027, with ongoing discussions regarding trial design and regulatory alignment.

• Open to partnerships but financially positioned to proceed independently.

• Positive Phase 2a data de-risk development and enhance visibility for value creation in the biotech platform.

• The company emphasizes its commitment to rapid development and commercialization of transformative therapies.